uniQure

Jonathan Garen, Chief Business Officer
Lexington, MA
(NASDAQ: QURE)
uniQure is delivering on the promise of gene therapy single treatments with potentially curative results. We are leveraging our modular and validated technology platform to rapidly advance a pipeline of proprietary and partnered gene therapies to treat patients with hemophilia, Huntington’s disease and other severe genetic diseases.
www.uniqure.com



By using this website you agree to accept our Privacy Policy and Terms & Conditions